110 related articles for article (PubMed ID: 5336511)
1. Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma.
Kyle RA; Carbone PP; Lynch JJ; Owens AH; Costa G; Silver RT; Cuttner J; Harley JB; Leone LA; Shnider BI; Holland JF
Cancer Res; 1967 Mar; 27(3):510-5. PubMed ID: 5336511
[No Abstract] [Full Text] [Related]
2. Evaluation of aniline mustard in patients with multiple myeloma.
Kyle RA; Costa G; Cooper MR; Ogawa M; Silver RT; Glidewell O; Holland JF
Cancer Res; 1973 May; 33(5):956-60. PubMed ID: 4703127
[No Abstract] [Full Text] [Related]
3. [1st experiences in the treatment of ovarian tumors with Peptichemio].
Natale N; Mangioni C; Remotti G
Minerva Med; 1974 May; 65(33):1805-10. PubMed ID: 4367233
[No Abstract] [Full Text] [Related]
4. [The results of a clinical study of asafan].
Karev NI; Lichinitser MR; Moroz LV; Astrakhan VI; Beroeva GV; Blokhina NG; Buk IM
Vopr Onkol; 1970 May; 16(5):41-5. PubMed ID: 5450810
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of mitozolomide in ovarian cancer.
Harding M; Northcott D; Smyth J; Stuart NS; Green JA; Newlands E
Br J Cancer; 1988 Jan; 57(1):113-4. PubMed ID: 3348943
[No Abstract] [Full Text] [Related]
6. Clinical trial of peptichemio in solid tumors of childhood.
Otten J; Maurus R
Cancer Treat Rep; 1978 Jul; 62(7):1015-9. PubMed ID: 356966
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of myeloma].
Le Chevallier PL
Therapeutique; 1971; 47(6):627-9. PubMed ID: 5571183
[No Abstract] [Full Text] [Related]
8. [The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
Chernyĭ VA
Vopr Onkol; 1970 Apr; 16(4):61-4. PubMed ID: 4989339
[No Abstract] [Full Text] [Related]
9. [Results of 18 months of chemotherapy with Peptichemio].
Battelli T; Bonsignori M; Manocchi P; Perilli A
Minerva Med; 1974 Sep; 65(62):3235-43. PubMed ID: 4609310
[No Abstract] [Full Text] [Related]
10. Abbreviated phase I clinical trial of i.v. mitozolomide.
Joss RA; Ryssel HJ; Bischoff AK; Goldhirsch A; Brunner KW
Cancer Treat Rep; 1986 Jun; 70(6):797-8. PubMed ID: 3524827
[No Abstract] [Full Text] [Related]
11. Treatment of multiple myeloma.
Langley GR; Smith FM
N S Med Bull; 1967 May; 46(5):105-8. PubMed ID: 5232995
[No Abstract] [Full Text] [Related]
12. A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.
Blackledge G; Roberts JT; Kaye S; Taylor R; Williams J; de Stavola B; Uscinska B
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):391-2. PubMed ID: 2702992
[No Abstract] [Full Text] [Related]
13. [Multiple myeloma--therapeutic outline].
Yamazaki T
Nihon Rinsho; 1970 Mar; 28():Suppl:1010-1. PubMed ID: 5464415
[No Abstract] [Full Text] [Related]
14. Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B.
Vinciguerra V; Anderson K; McIntyre OR
Cancer Treat Rep; 1985 Mar; 69(3):331-2. PubMed ID: 3884154
[No Abstract] [Full Text] [Related]
15. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
Knop S; Straka C; Haen M; Schwedes R; Hebart H; Einsele H
Haematologica; 2005 Sep; 90(9):1287-8. PubMed ID: 16154860
[TBL] [Abstract][Full Text] [Related]
16. [Comparative evaluation of results of treatment of patients with multiple myeloma with fractional doses of sarcolysine and asaline].
Kruglova GV; Merkulova NV; Panicheva EA
Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):21-4. PubMed ID: 5351083
[No Abstract] [Full Text] [Related]
17. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II clinical trial with mitoclomine (NSC-114575) in chronic lymphocytic leukemia.
Longeval E; Ganglji D; Stryckmans P; Kenis Y
Cancer Chemother Rep; 1975; 59(6):1173-5. PubMed ID: 769961
[No Abstract] [Full Text] [Related]
19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
20. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
